Teva EVP Richard Daniell sells 45,003 shares

Q: How many TEVA shares did Richard Daniell sell, and at what prices?

Richard Daniell sold 25,000 ordinary shares on November 9, 2026, at a weighted-average price of $42.9116 per share, with sale prices from $42.90 to $42.99. He sold 20,003 shares on November 11 at a weighted-average $42.8013 per share, with sale prices from $42.78 to $42.85.

Q: What were the exercise terms for Richard Daniell’s TEVA options?

He exercised 25,000 options on November 9, 2026 and 20,003 on November 11, each at a $34.70 exercise price. The options were granted on March 3, 2017; 11,250 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 11,253 vested on March 3, 2021.

Available on EDGAR 11/12/2026 - 04:16 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:15 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

TEVA EVP, Europe Commercial Richard Daniell exercised stock options and sold the resulting ordinary shares on November 9 and November 11, 2026.

On November 9, he exercised 25,000 options at a $34.70 exercise price and sold 25,000 shares at a weighted-average $42.9116 per share; sale prices ranged from $42.90 to $42.99. On November 11, he exercised 20,003 options at the same exercise price and sold 20,003 shares at a weighted-average $42.8013 per share; sale prices ranged from $42.78 to $42.85. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and Sale: 45,003 shares ($367K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Daniell Richard

Role EVP, Europe Commercial

Sold 45,003 shs ($1.93M)

Approx. gross sale proceeds $1.93M

Approx. exercise cost $1.56M

Approx. pre-tax spread $367K

Type	Security	Shares	Price	Value
Exercise	Stock Options (right to buy) ^F3	20,003	$0.00	$0.00
Exercise	Ordinary Shares	20,003	$34.70	$694K
Sale	Ordinary Shares ^F2	20,003	$42.8013	$856K
Exercise	Stock Options (right to buy) ^F3	25,000	$0.00	$0.00
Exercise	Ordinary Shares	25,000	$34.70	$868K
Sale	Ordinary Shares ^F1	25,000	$42.9116	$1.07M

Holdings After Transaction: Stock Options (right to buy) — 0 options (Direct); Ordinary Shares — 55,755 shares (Direct)

Footnotes (3)

F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.90 to $42.99, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.78 to $42.85, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3. Stock options were granted on March 3, 2017, with 11,250 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 11,253 vested on March 3, 2021.

Key Figures

Options exercised: 25,000 shares Exercise price: $34.70 per share Ordinary shares sold: 25,000 shares +5 more

8 metrics

Options exercised 25,000 shares November 9, 2026

Exercise price $34.70 per share Options exercised on November 9 and November 11, 2026

Ordinary shares sold 25,000 shares November 9, 2026

Weighted-average sale price $42.9116 per share November 9, 2026; sale prices ranged from $42.90 to $42.99

Options exercised 20,003 shares November 11, 2026

Ordinary shares sold 20,003 shares November 11, 2026

Weighted-average sale price $42.8013 per share November 11, 2026; sale prices ranged from $42.78 to $42.85

Shares sold 45,003 shares Total reported across the November 9 and November 11, 2026 transactions

Key Terms

weighted average price, exercise price, vested

3 terms

weighted average price financial

"The price reported was a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

exercise price financial

"Stock options exercised at a $34.70 exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested financial

"11,250 vested on March 3, 2018"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TEVA shares did Richard Daniell sell, and at what prices?

Richard Daniell sold 25,000 ordinary shares on November 9, 2026, at a weighted-average price of $42.9116 per share, with sale prices from $42.90 to $42.99. He sold 20,003 shares on November 11 at a weighted-average $42.8013 per share, with sale prices from $42.78 to $42.85.

What were the exercise terms for Richard Daniell’s TEVA options?

He exercised 25,000 options on November 9, 2026 and 20,003 on November 11, each at a $34.70 exercise price. The options were granted on March 3, 2017; 11,250 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 11,253 vested on March 3, 2021.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniell Richard

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV

6944020

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Europe Commercial

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	11/09/2026		M		25,000	A	$34.7	80,755	D
Ordinary Shares	11/09/2026		S		25,000	D	$42.9116⁽¹⁾	55,755	D
Ordinary Shares	11/11/2026		M		20,003	A	$34.7	75,758	D
Ordinary Shares	11/11/2026		S		20,003	D	$42.8013⁽²⁾	55,755	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (right to buy)	$34.7	11/09/2026		M			25,000	⁽³⁾	03/03/2027	Ordinary Shares	25,000	$0	20,003	D
Stock Options (right to buy)	$34.7	11/11/2026		M			20,003	⁽³⁾	03/03/2027	Ordinary Shares	20,003	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.90 to $42.99, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.78 to $42.85, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Stock options were granted on March 3, 2017, with 11,250 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 11,253 vested on March 3, 2021.

	/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR